By Chase Doyle
Originally published by our sister publication Clinical Oncology News
Chicago—The commonly used pain reliever acetaminophen may reduce the efficacy of immunotherapy in patients with cancer, according to a new study presented at the 2022 annual meeting of the American Society of Clinical Oncology (abstract 12000).
Analysis of plasma samples from more than 600 patients with advanced cancer found that acetaminophen use was associated with significantly worse outcomes among those